2023
Emerging Minimally Invasive Percutaneous Procedures for Periacetabular Osteolytic Metastases
Ibe I, Dussik C, Callan A, Barr J, Lee F. Emerging Minimally Invasive Percutaneous Procedures for Periacetabular Osteolytic Metastases. Journal Of Bone And Joint Surgery 2023, 105: 479-489. PMID: 36701566, DOI: 10.2106/jbjs.22.00694.Peer-Reviewed Original ResearchConceptsInvasive percutaneous proceduresOsteolytic metastasesInvasive proceduresPercutaneous proceduresCancer ablationOsteolytic skeletal metastasesOpen surgical managementPercutaneous screw fixationSystemic cancer therapyOpen surgical proceduresRestoration of ambulationComplex open surgical proceduresPeriacetabular osteolytic lesionsBalloon osteoplastyAmbulatory functionTotal hip reconstructionBlood lossOsteolytic lesionsSkeletal metastasesSurgical managementInterventional oncologistsInternal fixationSurgical proceduresInvasive techniquesScrew fixation
2021
Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19
Klein IA, Rosenberg SM, Reynolds KL, Zubiri L, Rosovsky R, Piper-Vallillo A, Gao X, Boland G, Bardia A, Gaither R, Freeman H, Kirkner GJ, Rhee C, Klompas M, Baker MA, Wadleigh M, Winer EP, Kotton CN, Partridge AH. Impact of Cancer History on Outcomes Among Hospitalized Patients with COVID-19. The Oncologist 2021, 26: 685-693. PMID: 33856099, PMCID: PMC8251362, DOI: 10.1002/onco.13794.Peer-Reviewed Original ResearchConceptsHistory of cancerIndependent risk factorDeath/hospiceSevere COVID-19Survivors of cancerHospitalized patientsCancer historyActive cancerRisk factorsCurrent cancer diagnosisCancer diagnosisCOVID-19Laboratory-confirmed COVID-19Intensive care unit admissionCare unit admissionOdds of intubationCancer-directed therapySystemic cancer therapyStandard anticancer therapiesRecent cancer treatmentUnit admissionHospice admissionMedian ageMedian timeMultivariable analysis
2020
The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM).
Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The association between clinical trial (CT) participation, pharmaceutical costs, and savings performance in the Oncology Care Model (OCM). Journal Of Clinical Oncology 2020, 38: 2-2. DOI: 10.1200/jco.2020.38.29_suppl.2.Peer-Reviewed Original ResearchOncology Care ModelDrug costsCancer CenterLung cancerEpisode costsMean MedicareYale Cancer CenterClinical trial participationSystemic cancer therapyPart D drug costsCancer therapyLower drug costsCommon cancer typesChi-square testPayment modelsClinical factorsNovel cancer therapiesTrial participationOvarian cancerPatient episodesNovel therapiesCare modelCTR groupPharmaceutical costsAlternative payment modelsAdoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life.
Riaz F, Gan G, Li F, Davidoff AJ, Adelson KB, Presley CJ, Adamson BJ, Shaw P, Parikh RB, Mamtani R, Gross CP. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life. JCO Oncology Practice 2020, 16: e1355-e1370. PMID: 32678688, PMCID: PMC8189605, DOI: 10.1200/op.20.00010.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsEnd of lifeUse of chemotherapySystemic cancer therapySystemic therapyCheckpoint inhibitorsColon cancerElectronic health record-derived databaseUse of ICIsFDA approvalCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerMSS colon cancerPearson's chi-square testDrug Administration approvalPatient-level dataCancer therapyDays of lifeChi-square testAggressive therapyBiologic therapyPatient characteristicsTreatment patternsThe impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM).
Adelson K, Canavan M, Mun S, Gross C, Sinanis N, Davidoff A. The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM). Journal Of Clinical Oncology 2020, 38: e19367-e19367. DOI: 10.1200/jco.2020.38.15_suppl.e19367.Peer-Reviewed Original ResearchOncology Care ModelDrug costsMean MedicareYale Cancer CenterMean drug costClinical trial participationSystemic cancer therapyLower drug costsCommon cancer typesChi-square testValue-based payment modelsPayment modelsClinical factorsCancer CenterTrial participationLung cancerEpisode costsCare modelCTR groupAlternative payment modelsCancer typesMean differenceCancer therapyCareEpisodesThe adoption of immune checkpoint inhibitors and patterns of care at the end of life.
Riaz F, Gan G, Li F, Davidoff A, Adelson K, Presley C, Adamson B, Shaw P, Parikh R, Mamtani R, Gross C. The adoption of immune checkpoint inhibitors and patterns of care at the end of life. Journal Of Clinical Oncology 2020, 38: 12027-12027. DOI: 10.1200/jco.2020.38.15_suppl.12027.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune checkpoint inhibitorsUse of chemotherapyMSS colon cancerEnd of lifeSystemic therapySystemic cancer therapyColon cancerFDA approvalCheckpoint inhibitorsBiologic therapyPatient characteristicsUse of ICIsCell lung cancerPatterns of careCare of patientsMicrosatellite stable colon cancerPearson's chi-square testPatient-level dataCancer therapyDays of lifeDe-identified databaseSignificant increaseChi-square testAggressive therapy
2019
Dermatologic conditions in women receiving systemic cancer therapy
Ferreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. International Journal Of Women's Dermatology 2019, 5: 285-307. PMID: 31909148, PMCID: PMC6938835, DOI: 10.1016/j.ijwd.2019.10.003.Peer-Reviewed Original ResearchDermatologic conditionsDermatologic toxicitiesCancer therapyDermatologic adverse effectsCancer-related survivalImmune checkpoint inhibitorsNumber of patientsSystemic cancer therapyQuality of lifeCheckpoint inhibitorsEndocrine therapyOverall survivalMultidisciplinary careTimely diagnosisTreatment responseTraditional chemotherapyMucosal surfacesTherapyNovel therapeuticsMental healthAdverse effectsWomenToxic effectsCancerSevere instances
2011
A Comprehensive Review of MR Imaging Changes following Radiosurgery to 500 Brain Metastases
Patel TR, McHugh BJ, Bi WL, Minja FJ, Knisely JP, Chiang VL. A Comprehensive Review of MR Imaging Changes following Radiosurgery to 500 Brain Metastases. American Journal Of Neuroradiology 2011, 32: 1885-1892. PMID: 21920854, PMCID: PMC7966021, DOI: 10.3174/ajnr.a2668.Peer-Reviewed Original ResearchConceptsBrain metastasesMedian survivalMetastatic lesionsLesion sizeMost metastatic lesionsMR imaging changesPercent of lesionsInitial treatment volumeSystemic cancer therapyInitial lesion sizeIntracranial metastatic lesionsGK-SRSLesional responsePatient demographicsRadiographic responseInitial treatmentImaging changesMale sexTumor sizeLesion volumeStereotactic radiosurgeryTreatment dosePatientsLesionsRadiosurgery
2010
Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Curigliano G, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress In Cardiovascular Diseases 2010, 53: 94-104. PMID: 20728696, DOI: 10.1016/j.pcad.2010.05.006.Peer-Reviewed Original ResearchConceptsCardiac adverse effectsCardiac toxicityCardiovascular toxicityNew drug developmentLeft ventricular ejection fraction declineVentricular ejection fraction declineAdverse effectsClassic chemotherapy agentsEjection fraction declinePotential cardiovascular toxicityRare serious complicationsNovel biologic agentsSignificant cardiac dysfunctionAcute coronary syndromeCongestive heart failureLong-term complicationsTypes of malignanciesSystemic cancer therapyLife-threatening eventsCancer therapyTyrosine kinase inhibitorsDrug developmentCardiovascular safetyCoronary syndromeBiologic agents
2007
Phase I trial of intravenous 17-allylaminogeldanamycin (A) and oral sorafenib (B) in pretreated advanced malignancy: Plasma Hsp90α induction correlates with clinical benefit
Vaishampayan U, Sausville E, Horiba M, Quinn M, Heilbrun L, Burger A, Ivy P, Li J, Lorusso P. Phase I trial of intravenous 17-allylaminogeldanamycin (A) and oral sorafenib (B) in pretreated advanced malignancy: Plasma Hsp90α induction correlates with clinical benefit. Journal Of Clinical Oncology 2007, 25: 3531-3531. DOI: 10.1200/jco.2007.25.18_suppl.3531.Peer-Reviewed Original ResearchAdvanced malignanciesClinical benefitGrade 3 hand-foot syndromeAdequate organ functionGrade 2 nauseaGrade 3 fatigueResponse-evaluable patientsHand-foot syndromePhase II dosePhase I trialSystemic cancer therapyDose cohortsEvaluable patientsInevaluable patientsNCI-CTEPOral sorafenibStable diseaseB. PatientsClinical responseFoot syndromeLatter patientsMajor toxicityPartial responsePerformance statusStable patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply